6998-60-3 Usage
Description
RIFAMYCIN SV, also known as Rifogal, is a member of the rifamycin class of antibiotics. It possesses antibiotic and antitubercular properties, making it a crucial component of the antibacterial arsenal. RIFAMYCIN SV functions by inhibiting bacterial RNA polymerase (RNAP), which is an essential part of bacterial replication and transcription processes.
Uses
Used in Pharmaceutical Industry:
RIFAMYCIN SV is used as an antibacterial drug for treating various bacterial infections. It is particularly effective against Mycobacterium avium complex (MAC), which is responsible for lung diseases. RIFAMYCIN SV is used as a part of multidrug regimens to combat MAC-induced lung diseases, providing a valuable treatment option for patients suffering from these conditions.
Additionally, RIFAMYCIN SV's ability to inhibit bacterial RNA polymerase makes it a potential candidate for further research and development in the pharmaceutical industry, possibly leading to the discovery of new antibiotics or antitubercular drugs.
Pharmaceutical Applications
The simplest rifamycin in clinical use, obtained by elimination of a glycolic moiety from rifamycin B. Formulated as sodium salt for parenteral administration. Also available for topical use. Its activity, general properties and pharmacokinetics are very similar to those of rifamide. It is orally absorbed and excreted mainly in the bile. Intramuscular doses of 250 mg produce mean plasma levels of about 2 mg/L. The plasma half-life is around 2 h.In addition to uses similar to those of rifamide, it is administered topically in surgery and has been proposed for the treatment of synovitis by intra-articular injections. A topical preparation is used for application to wounds and bedsores. Cases of anaphylactic reactions have been reported after local administration of the drug.
Purification Methods
Rifamycin SV gives yellow-orange crystals from Et2O/pet ether or aqueous EtOH, is very soluble in MeOH, EtOH, Me2CO and EtOAc, and is less soluble in Et2O and HCO3-, but slightly soluble in H2O and pet ether. Its UV has max at 223, 314 and 445nm ( 1cm 586, 322 and 204) in phosphatebuffer pH 7. [NMR: Bergamini & Fowst Arzneim.-Forsch 15 951 1965.]
Check Digit Verification of cas no
The CAS Registry Mumber 6998-60-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,9,9 and 8 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 6998-60:
(6*6)+(5*9)+(4*9)+(3*8)+(2*6)+(1*0)=153
153 % 10 = 3
So 6998-60-3 is a valid CAS Registry Number.
InChI:InChI=1/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,25-,29-,30+,33+,37-/m0/s1
6998-60-3Relevant articles and documents
3-(SUBSTITUTED ETHYL)-RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS
-
Page/Page column 15, (2010/03/02)
The present invention is directed to novel 3-(substituted ethyl) rifamycin derivatives, pharmaceutical compositions containing them and the use of said derivatives and pharmaceutical compositions as antimicrobial agents against pathogenic microorganisms, particularly against resistant microbes.
Process for preparing rifamycin derivatives
-
, (2008/06/13)
3-Dialkylaminomethyl derivatives of rifamycin S is provided by reacting rifamycin S with an iminium salt in an organic solvent. This compound is converted to 3-dialkylaminomethyl derivatives by virtue of ascorbic acid.
